Momenta Pharmaceuticals, Inc. - News/Events - Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

10/01/2020

Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson

09/15/2020

Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson

08/19/2020

Momenta Enters Definitive Agreement with Johnson & Johnson

08/10/2020

Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results

08/03/2020

Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast

07/28/2020

Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN

06/15/2020

Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)

05/07/2020

Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results

04/23/2020

Momenta Pharmaceuticals Announces Date of First Quarter 2020 Financial Results Conference Call and Webcast

04/02/2020

Momenta Provides Corporate Update Amid COVID-19 Pandemic

02/26/2020

Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

02/19/2020

Momenta Pharmaceuticals to Webcast Presentation at the Cowen 40th Annual Health Care Conference

02/12/2020

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2019 Financial Results Conference Call and Webcast

01/13/2020

Momenta Provides Year-End 2019 Update and 2020 Outlook

01/03/2020

Momenta Pharmaceuticals Announces CFO Transition